Related Experiment Video
Updated: Sep 12, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
New frontiers in prostate cancer treatment from systemic therapy to targeted therapy
Shaghayegh Nouruzi1,2, Maxim Kobelev1,2, Nakisa Tabrizian1,2
1Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.
Abstract:
Significant advances in prostate cancer (PCa) treatment have occurred through the integration of molecular biomarkers and imaging with targeted therapies. While androgen receptor pathway inhibition (ARPI) remains the cornerstone of PCa therapy, the current therapeutic landscape has expanded to include a broader range of targeted agents, alongside emerging approaches that leverage disease-specific vulnerabilities. Molecular profiling has enabled the exploration of diverse therapeutic modalities, including epigenetic regulators, immune-modulating agents, metabolic pathways, kinases, and cell surface proteins. Despite this progress, further research is needed to address tumour heterogeneity and treatment-resistant phenotypes. As ARPI use moves earlier in the disease course and novel agents are incorporated into standard care, prolonging disease control may also reshape emergent resistant phenotypes and disease progression trajectories. This evolving context underscores the need to revisit agents that may now show efficacy in new therapeutic settings or when paired with complementary strategies. Here, we review the current treatment framework in PCa and highlight novel approaches and targets poised to transform clinical care.
Insights
Prostate cancer (PCa) treatments are advancing with targeted therapies and molecular biomarkers. New approaches are emerging to overcome treatment resistance and improve outcomes for patients with advanced prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Prostate cancer (PCa) treatment has evolved significantly with molecular biomarkers and imaging guiding targeted therapies.
- Androgen receptor pathway inhibition (ARPI) is central, but the landscape now includes diverse targeted agents addressing specific vulnerabilities.
- Tumor heterogeneity and resistance necessitate ongoing research into novel therapeutic strategies.
Purpose of the Study:
- To review the current prostate cancer treatment framework.
- To highlight novel therapeutic approaches and targets in PCa.
- To discuss the impact of evolving treatment paradigms on resistance mechanisms.
Main Methods:
- Review of current literature on prostate cancer therapeutics.
- Analysis of emerging targeted agents and molecular profiling data.
- Discussion of resistance mechanisms and future therapeutic directions.
Main Results:
- The therapeutic landscape for PCa has expanded beyond ARPI to include epigenetic, immune, metabolic, kinase, and cell surface targets.
- Early ARPI use and novel agents may alter resistance phenotypes and disease progression.
- Revisiting existing agents in new contexts or combinations may enhance efficacy.
Conclusions:
- Advances in molecular profiling and targeted therapies are transforming PCa treatment.
- Addressing tumor heterogeneity and resistance remains critical for improving patient outcomes.
- Novel agents and strategies are poised to significantly impact future clinical care for prostate cancer.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy